ICURE, a Korean biopharmaceutical company, has signed an export agreement with ANDK, a U.K.-based pharmaceutical trading company, to supply local anesthetics Plaster and Cataplasma in the Middle East and North Africa (MENA) region, including Kuwait, the UAE, and Egypt.

ICURE specializes in the development and production of its products based on Transdermal Drug Delivery System (TDDS) technology.

The contract is for the supply of ICURE’s products worth $5 million over five years.

"ANDK is a company that we discovered in Europe last year, and it is even more meaningful to finalize the contract after a year of negotiations. We aim to become a global company by increasing not only domestic sales but also overseas sales," said Lee Young-seok, CEO of ICURE.

In February, ICURE signed a deal with Menarini Asia-Pacific, a subsidiary of Italian pharmaceutical company Menarini Group, to distribute stick-on type of donepezil products in Taiwan and other parts of Southeast Asia. The deal with Menarini Asia-Pacific is worth an estimated 54 billion won.